STOCK TITAN
  1. Home
  2. Sec-filings
  3. TRSO
  4. [8-K] TRANSUITE.ORG INC. Reports Material Event

Transuite.org (TRSO) reshapes board, appoints Hailiang Li as new CFO

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Transuite.org Inc. reported significant board and leadership changes effective February 12, 2026, as part of a corporate governance and management realignment. Four directors — Jie Zhou, Yifan Wang, Qianglong Zeng, and Wei Zhen — resigned from the Board but were simultaneously appointed as consultants to continue supporting the company in advisory roles.

On the same date, Wei Zhen resigned as Chief Financial Officer, and the Board appointed Hailiang Li as the new CFO. The company highlights Mr. Li’s more than 20 years of experience in corporate management, financial management, corporate governance, strategic planning, and digital transformation. The filing states that the resignations were not due to any disagreement with the company and that Mr. Li’s appointment did not arise from any arrangements with other persons or family relationships.

Positive

  • None.

Negative

  • None.

Insights

Transuite.org restructures board and CFO role, keeping former directors as advisors.

Transuite.org Inc. is reshaping governance by transitioning four directors off the Board while retaining them as consultants. This keeps institutional knowledge accessible while allowing a refreshed board structure and a new financial leadership profile through the appointment of a new Chief Financial Officer.

The company appointed Hailiang Li as CFO, emphasizing his two decades of experience in financial management, corporate governance, strategic planning, and digital transformation. The filing explicitly notes that director and CFO resignations were not due to disagreements and that there are no special arrangements or family relationships tied to his appointment, framing the shift as an organized realignment rather than a dispute-driven change.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Understanding 8-K Material Events →

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 12, 2026

 

TRANSUITE.ORG INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

333-255178

 

30-1129581

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

 

 

732 S 6th St # 4304

Las Vegas, NV 89101

 

(Address of Principal Executive Offices)

 

(775) 295-4295

Registrant’s telephone number, including area code

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (2§40.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Appointment of Certain Officers

 

Effective February 12, 2026, as part of a corporate governance and management realignment, Jie Zhou, Yifan Wang, Qianglong Zeng, and Wei Zhen resigned from their positions as members of the Board of Directors of the Company， and simultaneously each of the foregoing individuals was appointed to serve as a consultant to the Company and will continue to support the Company in advisory capacities, effective immediately.

 

Effective February 12, 2026, Wei Zhen resigned from his position as Chief Financial Officer of the Company, and the Board of Directors appointed Hailiang Li to serve as Chief Financial Officer of the Company.

 

Mr. Li graduated from the School of Management at Xi’an Jiaotong University. He previously served as Deputy Secretary-General of the Sun Yat-sen Center Foundation and as General Manager of Shanghai Shanguan Culture Communication Co., Ltd. He currently serves as the Founder and Chief Executive Officer of Xirangsheng (Shenzhen) Health Technology Co., Ltd. Mr. Li has over 20 years of experience in corporate management and operations, including experience in financial management, corporate governance, strategic planning, and digital transformation initiatives.

 

The foregoing resignations were not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

 

There are no arrangements or understandings between Mr. Li and any other person pursuant to which he was appointed as Chief Financial Officer. There are no family relationships between Mr. Li and any director or executive officer of the Company.

 

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

TRANSUITE.ORG INC.

 

Date: February 12, 2026

By:

/s/ Mengqing Fan

 

 

 

Name: Mengqing Fan

 

 

 

Title: Chief Executive Officer, Director,

Chairwoman of the Board

 

 

 

3

  

Source: View Original Filing on SEC EDGAR

FAQ

What leadership changes did Transuite.org Inc. (TRSO) disclose in this 8-K?

Transuite.org Inc. reported that four directors resigned from the Board and were appointed as consultants, and that Wei Zhen resigned as Chief Financial Officer. The Board simultaneously appointed Hailiang Li as the new CFO, effective February 12, 2026, as part of a governance realignment.

Who is the new Chief Financial Officer of Transuite.org Inc. (TRSO)?

The new Chief Financial Officer is Hailiang Li. He holds a degree from Xi’an Jiaotong University’s School of Management and has over 20 years of experience in corporate management, including financial management, corporate governance, strategic planning, and digital transformation initiatives across multiple organizations.

Why did the directors resign from the Transuite.org Inc. (TRSO) Board?

The filing states the four directors resigned as part of a corporate governance and management realignment. It also clarifies that their resignations were not due to any disagreement with the company regarding its operations, policies, or practices, and they will remain as consultants in advisory roles.

Will the departing Transuite.org Inc. (TRSO) directors still be involved with the company?

Yes. Although Jie Zhou, Yifan Wang, Qianglong Zeng, and Wei Zhen resigned as directors, each was simultaneously appointed as a consultant. They will continue to support Transuite.org Inc. in advisory capacities, helping maintain continuity while the formal board composition changes.

Are there any special arrangements behind the appointment of Transuite.org Inc.’s new CFO?

The filing states there are no arrangements or understandings between Hailiang Li and any other person under which he was appointed as Chief Financial Officer. It also confirms there are no family relationships between him and any director or executive officer of Transuite.org Inc.

Filing Exhibits & Attachments

5 documents

Other Documents